| Literature DB >> 17126963 |
Janie Parrino1, Lewis H McCurdy, Brenda D Larkin, Ingelise J Gordon, Steven E Rucker, Mary E Enama, Richard A Koup, Mario Roederer, Robert T Bailer, Zoe Moodie, Lin Gu, Lihan Yan, Barney S Graham.
Abstract
Modified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax in vaccinia-naïve and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or placebo followed by Dryvax challenge at 3 months. Two or more doses of MVA prior to Dryvax reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax vaccinia-specific CD8(+) T cell responses and extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17126963 PMCID： PMC1892755 DOI： 10.1016/j.vaccine.2006.10.047
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641